Journal
CANCERS
Volume 12, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/cancers12092359
Keywords
Genome of advanced melanoma; acral; mucosal; uveal; melanoma of unknown origin; tumor mutation burden; TMB; immune checkpoint inhibitors; next-generation sequencing
Categories
Funding
- TUFF Habilitation Program for Women of the Faculty of Medicine Tubingen, Germany [2521-0-0]
- Deutsche Forschungsgemeinschat (German Research Foundation) under Germany's Excellence Strategy [EXC 2180-390900677]
Ask authors/readers for more resources
The detection of somatic driver mutations by next-generation sequencing (NGS) is becoming increasingly important in the care of advanced melanoma patients. In our study, we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017. Besides determining the tumor mutational burden (TMB) and annotation of all genetic driver alterations, we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI) and as a distinguishing feature between melanoma subtypes. Melanomas of unknown primary had a similar mutation pattern and TMB to cutaneous melanoma, which hints at its cutaneous origin. Besides the typical hotspot mutation in BRAF and NRAS, we frequently observed CDKN2A deletions. Acral and mucosal melanomas were dominated by CNV alterations affecting PDGFRA, KIT, CDK4, RICTOR, CCND2 and CHEK2. Uveal melanoma often had somatic SNVs in GNA11/Q and amplification of MYC in all cases. A significantly higher incidence of BRAF V600 mutations and EGFR amplifications, PTEN and TP53 deletions was found in patients with disease progression while on ICI. Thus, NGS might help to characterize melanoma subtypes more precisely and to identify possible resistance mechanisms to ICI therapy. Nevertheless, NGS based studies, including larger cohorts, are needed to support potential genetic ICI resistance mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available